title: [Node negative breast cancer. Beyond international consensus: a pragmatic approach].
abstract: Apart from therapeutic advances related to new treatments, our practices in the management of early breast cancer have been modified by to key organizational settings (1) mass screening, substantially altering the presentation and epidemiology of breast cancer and (2) the development of guidelines to ensure that any patient management is in agreement with the demonstrated impact in the adjuvant treatment. In daily practice, the impact of screening and guidelines recommendations has put us now in a paradoxical situation: while the majority of non-metastatic breast cancers treated in the hexagon are node negative, most of the results of clinical studies on chemotherapy and targeted therapies today arise from populations predominantly node positive. Therefore, it seemed legitimate to convene a working group around a reflection on the directions of adjuvant chemotherapy in a growing node negative population in order to better respond to the questions of the field oncologists, trying to address the discrepancies between different existing guidelines.
authors: Centre Jean-Perrin, service de pathologie, 58, rue Montalembert BP 392, 63011 Clermont-Ferrand, France. fpenault@cjp.fr
authors: Frédérique
authors: F
authors: Penault-Llorca
authors: David
authors: D
authors: Coeffic
authors: Thierry
authors: T
authors: Delozier
authors: Nadine
authors: N
authors: Dohollou
authors: Gilles
authors: G
authors: Freyer
authors: Joseph
authors: J
authors: Gligorov
authors: Anne-Claire
authors: AC
authors: Hardy-Bessard
authors: William
authors: W
authors: Jacot
authors: Jean-Louis
authors: JL
authors: Misset
authors: Jean-Marc
authors: JM
authors: Nabholtz
authors: Thierry
authors: T
authors: Petit
authors: Marc
authors: M
authors: Spielmann
authors: Moïse
authors: M
authors: Namer
mesh_terms: D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000592:standards; D005260:Female; D005602:France; D018734:Genes, erbB-2 / Q000235:genetics; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D000068878:Trastuzumab; D047368:Tumor Burden
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D000068878:Trastuzumab